SCHEMBL369593

SCHEMBL369593

COC(=O)c1nc2c(NC(=O)C(=O)N(C)C)cc(N3CCOCC3)cn2c(=O)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.41
PIK3CB P42338 5/20 0.38
PIK3CA P42336 4/20 0.38
PIK3CD O00329 3/20 0.38
CYP3A4 P08684 1/20 0.37
LRRK2 Q5S007 1/20 0.37
SLCO1B1 Q9Y6L6 1/20 0.37
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MAPK14 Q16539 1/20 0.37
CASP1 P29466 2/20 0.36
HSD17B10 Q99714 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15091802 0.90 KDM4E (0.44) MRGPRX4PIK3CBPIK3CAPIK3CDCYP3A4
SCHEMBL10070438 0.87 MAPT (0.37) MRGPRX4CYP3A4LRRK2ALDH1A1KDM4E
SCHEMBL367770 0.86 MRGPRX4 (0.45) MRGPRX4PIK3CBPIK3CAPIK3CDCYP3A4
SCHEMBL1221944 0.84 MRGPRX4 (0.45) MRGPRX4PIK3CBPIK3CACYP3A4LRRK2
SCHEMBL1222487 0.84 MRGPRX4 (0.41) MRGPRX4PIK3CBPIK3CAPIK3CDCYP3A4
SCHEMBL15092128 0.84 MRGPRX4 (0.42) MRGPRX4PIK3CBPIK3CAPIK3CDCYP3A4
SCHEMBL12880836 0.84 MRGPRX4 (0.44) MRGPRX4PIK3CBPIK3CACYP3A4LRRK2
SCHEMBL369064 0.83 MAPT (0.38) PIK3CBPIK3CAPIK3CDALDH1A1KDM4E
SCHEMBL1222490 0.83 MRGPRX4 (0.41) MRGPRX4PIK3CBPIK3CAPIK3CDCYP3A4
SCHEMBL12880835 0.82 MRGPRX4 (0.43) MRGPRX4PIK3CBPIK3CACYP3A4LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 MRGPRX4 313/4885PIK3CB 1445/4885PIK3CA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.